Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Although the use of bortezomib has reported efficacy in amyloid light chain (AL) amyloidosis,
the role of bortezomib with dexamethasone (BD) in the first-line treatment of patients with
AL amyloidosis should be determined. In this study, the investigators evaluated the efficacy
and safety of BD as the first-line treatment of patients with AL amyloidosis.
Details
Lead Sponsor:
Zhi-Hong Liu, M.D.
Treatments:
Antibodies BB 1101 Bence Jones Protein Bortezomib Dexamethasone Dexamethasone 21-phosphate Dexamethasone acetate Immunoglobulin Light Chains Immunoglobulins